CNTB vs. ALLK, ACET, RLMD, PMVP, CTXR, CRVS, BYSI, ORMP, ASRT, and CLRB
Should you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include Allakos (ALLK), Adicet Bio (ACET), Relmada Therapeutics (RLMD), PMV Pharmaceuticals (PMVP), Citius Pharmaceuticals (CTXR), Corvus Pharmaceuticals (CRVS), BeyondSpring (BYSI), Oramed Pharmaceuticals (ORMP), Assertio (ASRT), and Cellectar Biosciences (CLRB). These companies are all part of the "pharmaceutical preparations" industry.
Allakos (NASDAQ:ALLK) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership, community ranking and valuation.
Allakos received 165 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 69.57% of users gave Connect Biopharma an outperform vote while only 59.34% of users gave Allakos an outperform vote.
In the previous week, Allakos had 1 more articles in the media than Connect Biopharma. MarketBeat recorded 1 mentions for Allakos and 0 mentions for Connect Biopharma. Allakos' average media sentiment score of 1.89 beat Connect Biopharma's score of 0.09 indicating that Connect Biopharma is being referred to more favorably in the news media.
Allakos has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.49, meaning that its share price is 149% less volatile than the S&P 500.
Allakos presently has a consensus price target of $1.83, indicating a potential upside of 27.31%. Connect Biopharma has a consensus price target of $6.50, indicating a potential upside of 265.17%. Given Allakos' stronger consensus rating and higher probable upside, analysts clearly believe Connect Biopharma is more favorable than Allakos.
Allakos' return on equity of 0.00% beat Connect Biopharma's return on equity.
84.6% of Allakos shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 16.1% of Allakos shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Connect Biopharma beats Allakos on 8 of the 12 factors compared between the two stocks.
Get Connect Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Connect Biopharma Competitors List
Related Companies and Tools